Literature DB >> 22386373

Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma.

Bradford S Hoppe1, Stella Flampouri, Zhong Su, Naeem Latif, Nam H Dang, James Lynch, Michael Joyce, Eric Sandler, Zuofeng Li, Nancy P Mendenhall.   

Abstract

PURPOSE: We investigated the dosimetric impact of proton therapy (PT) on various cardiac subunits in patients with Hodgkin lymphoma (HL). METHODS AND MATERIALS: From June 2009 through December 2010, 13 patients were enrolled on an institutional review board-approved protocol for consolidative involved-node radiotherapy (INRT) for HL. Three separate treatment plans were developed prospectively by using three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), and PT. Cardiac subunits were retrospectively contoured on the 11 patients with intravenous-contrast simulation scans, and the doses were calculated for all treatment plans. A Wilcoxon paired test was performed to evaluate the statistical significance (p < 0.05) of 3DCRT and IMRT compared with PT.
RESULTS: The mean heart doses were 21 Gy, 12 Gy, and 8 Gy (relative biologic effectiveness [RBE]) with 3DCRT, IMRT, and PT, respectively. Compared with 3DCRT and IMRT, PT reduced the mean doses to the left and right atria; the left and right ventricles; the aortic, mitral, and tricuspid valves; and the left anterior descending, left circumflex, and right circumflex coronary arteries.
CONCLUSIONS: Compared with 3DCRT and IMRT, PT reduced the radiation doses to all major cardiac subunits. Limiting the doses to these structures should translate into lower rates of cardiac toxicities.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22386373     DOI: 10.1016/j.ijrobp.2011.12.034

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  42 in total

Review 1.  The concept and evolution of involved site radiation therapy for lymphoma.

Authors:  Lena Specht; Joachim Yahalom
Journal:  Int J Clin Oncol       Date:  2015-07-07       Impact factor: 3.402

2.  [Risk of heart failure in patients with Hodgkin lymphoma after radiation and anthracycline chemotherapy].

Authors:  J Kriz; H T Eich
Journal:  Strahlenther Onkol       Date:  2017-08       Impact factor: 3.621

3.  Radiation induced valvular disease: the internist's prospective.

Authors:  Sundeep Kumar; Hiren Patel; Joyce Paulson; Bernard Gros
Journal:  BMJ Case Rep       Date:  2019-01-22

Review 4.  Proton therapy for Hodgkin lymphoma.

Authors:  Michael S Rutenberg; Stella Flampouri; Bradford S Hoppe
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

5.  Radiation-induced heart disease: an under-recognized entity?

Authors:  Margot Davis; Ronald M Witteles
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-06

Review 6.  ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.

Authors:  Sughosh Dhakal; Ranjana Advani; Leslie K Ballas; Bouthaina S Dabaja; Christopher R Flowers; Chul S Ha; Bradford S Hoppe; Nancy P Mendenhall; Monika L Metzger; John P Plastaras; Kenneth B Roberts; Ronald Shapiro; Sonali M Smith; Stephanie A Terezakis; Karen M Winkfield; Anas Younes; Louis S Constine
Journal:  Am J Clin Oncol       Date:  2016-12       Impact factor: 2.339

Review 7.  Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.

Authors:  Annette E Hay; Ralph M Meyer
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

Review 8.  Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment.

Authors:  Johan Spetz; Javid Moslehi; Kristopher Sarosiek
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-20

Review 9.  Clinical controversies: proton therapy for pediatric tumors.

Authors:  Thomas E Merchant
Journal:  Semin Radiat Oncol       Date:  2013-04       Impact factor: 5.934

Review 10.  Charged particle therapy--optimization, challenges and future directions.

Authors:  Jay S Loeffler; Marco Durante
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.